KLOW peptide dosing protocol
KLOW comes as a lyophilized powder in an 80 mg vial containing all four compounds pre-blended. Dosing requires reconstitution with bacteriostatic water, calculation of the correct injection volume, and a titration period to assess tolerance. This page covers the complete KLOW dosing protocol — reconstitution math, titration schedule, injection technique, cycle length, and storage.
KLOW peptide vial composition
A standard KLOW vial contains 80 mg total peptide across the four compounds. The typical breakdown is GHK-Cu 50 mg, BPC-157 10–15 mg, TB-500 10–15 mg, and KPV 10 mg. Because the compounds are pre-blended and lyophilized together, you cannot adjust the ratio of individual components — the dose of each compound scales proportionally with the total injection volume.
Reconstitution math
Add 3.0 mL of bacteriostatic water to the 80 mg vial. This produces a concentration of 26.67 mg/mL total peptide. On a U-100 insulin syringe, 1 unit (0.01 mL) = 267 mcg total peptide. Inject the water slowly down the inside wall of the vial — do not spray directly onto the powder. Gently swirl or roll the vial until dissolved. Do not shake.
KLOW titration schedule
Titration allows the body to adjust to the four-compound blend and helps identify any individual sensitivity before reaching the full dose. The following schedule uses the standard 3.0 mL reconstitution.
| Week | Units (U-100 syringe) | Volume | Total peptide per dose | Notes |
|---|---|---|---|---|
| Week 1 | 10 units | 0.10 mL | 2.67 mg | Starting dose. Assess tolerance — watch for injection site reaction, nausea, headache. |
| Week 2 | 15 units | 0.15 mL | 4.0 mg | First increase. Most users tolerate this well. |
| Week 3+ | 20 units | 0.20 mL | 5.33 mg | Standard maintenance dose. Continue at this level for the remainder of the cycle. |
At the standard maintenance dose of 20 units daily, one 80 mg vial lasts approximately 15 days (3.0 mL ÷ 0.20 mL per dose = 15 doses). A 30-day cycle requires two vials. Some protocols use lower daily doses (10–15 units) for longer duration, particularly when the primary goal is anti-inflammatory support or skin rejuvenation rather than acute tissue repair.
KLOW peptide injection protocol
KLOW is administered as a subcutaneous injection — into the fat layer beneath the skin, not into a vein or muscle. The standard injection sites are the lower abdomen (at least 2 inches from the navel), the front of the thigh, or the upper arm. Rotate between sites with each injection to prevent lipodystrophy.
Most KLOW protocols call for once-daily injection, typically in the evening or before bed. Evening dosing is preferred by many users because GHK-Cu and TB-500 may support recovery processes that are active during sleep, though this timing preference is based on anecdotal reports rather than controlled studies. The injection can be given at any time of day with or without food.
Use an insulin syringe (29–31 gauge, ½-inch needle) for subcutaneous injection. Pinch a fold of skin at the injection site, insert the needle at a 45-degree angle, inject slowly, hold for 5 seconds, then withdraw. For small volumes (10–15 units during titration), a 30-unit or 50-unit insulin syringe provides better readability than a standard 100-unit syringe.
KLOW cycle length
Published dosing guidelines for KLOW are limited since it is a relatively new blend. Based on the standalone cycling data for its component peptides and community protocols, common cycle approaches include a 4-week acute cycle for injury recovery or post-surgical healing (2–3 vials), a 6–8 week standard cycle for general recovery, gut healing, or skin rejuvenation (4–5 vials), and an 8–12 week extended cycle for chronic conditions or comprehensive anti-aging protocols (5–8 vials).
Most protocols include an off-period between cycles — typically 4 weeks — to allow the body's endogenous repair mechanisms to normalize. Whether cycling is necessary for the KLOW blend specifically has not been studied; the recommendation is borrowed from standalone BPC-157 and TB-500 protocols where tolerance and receptor sensitivity are theoretical concerns with continuous use.
KLOW peptide storage and handling
Unreconstituted (lyophilized) KLOW should be stored frozen at -20°C (-4°F) for long-term storage or refrigerated at 2–8°C (35–46°F) for short-term storage (up to several months). Once reconstituted with bacteriostatic water, KLOW must be refrigerated at 2–8°C and used within 28–30 days. Do not freeze reconstituted KLOW — freezing and thawing can denature the peptides and reduce potency. Do not use the solution if it appears cloudy, discolored, or contains visible particles.
Keep the vial away from direct sunlight and excessive heat. Use a clean alcohol swab on the vial stopper before each draw. Use a new sterile syringe for each injection — never reuse needles or syringes.
Can I use more or less bacteriostatic water than 3 mL?
Yes. The amount of water only changes the concentration, not the total peptide content. Using 2 mL produces a more concentrated solution (40 mg/mL, 400 mcg per unit) with smaller injection volumes. Using 4 mL produces a more dilute solution (20 mg/mL, 200 mcg per unit) with larger injection volumes. Adjust your syringe units proportionally. The 3 mL standard provides a good balance of concentration and volume readability on a U-100 syringe.
Can I inject KLOW at the injury site?
Some practitioners recommend subcutaneous injection near (not directly into) the injury site for localized tissue repair, on the theory that higher local concentrations of BPC-157 and TB-500 may accelerate healing at that specific location. This approach is borrowed from standalone BPC-157 protocols. However, the KLOW blend's systemic effects (particularly KPV's anti-inflammatory and GHK-Cu's matrix-remodeling effects) work regardless of injection location, so abdominal injection is also effective for localized injuries.
What if I miss a dose?
Missing a single dose is unlikely to meaningfully impact results. Simply resume the next scheduled dose — do not double up. If you miss multiple consecutive days, you do not need to restart the titration schedule as long as you were previously tolerating the maintenance dose without issues.